Arch Biopartners (TSE:ARCH)

:ARCH

ARCH

Arch Biopartners

RESEARCH TOOLSreports

Want to see TSE:ARCH full AI Analyst Report?

Arch Biopartners (ARCH) Price & Analysis

48 Followers

ARCH Stock Chart & Stats

C$1.37

-C$0.06(-3.14%)

At close: Jan 08 4:00 PM EST

C$1.37

-C$0.06(-3.14%)

Day’s Range― - ―

52-Week RangeC$0.39 - C$1.93

Previous CloseN/A

Volume5.12K

Average Volume (3M)43.97K

Market Cap

C$32.27M

Enterprise ValueC$32.86M

Total Cash (Recent Filing)C$436.76K

Total Debt (Recent Filing)C$2.73M

Price to Earnings (P/E)―

Beta0.84

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding67,933,290

10 Day Avg. Volume31,059

30 Day Avg. Volume43,967

Financial Highlights & Ratios

PEG Ratio0.88

Price to Book (P/B)-21.63

Price to Sales (P/S)0.00

P/FCF Ratio-53.01

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.16

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Narrowing Losses And Debt ReductionRecent narrowing of net losses alongside a reduction in outstanding debt suggests improving financial discipline and a modestly stronger runway. This durable improvement can lower near-term financing pressure, enhance partner negotiations for deals, and support continued clinical progress if trends persist.

Antibody Discovery Platform Focused On Acute Inflammation/ARDSA platform-driven monoclonal antibody approach targeting acute inflammation and ARDS provides structural advantages: the platform can yield multiple candidates, targets high unmet clinical need in critical care, and creates a durable basis for partnerships, licensing, or acquisition interest.

Partnership/licensing Monetization ModelA business model emphasizing licensing, co-development, milestone payments and royalties is well-suited to a clinical-stage biotech. It reduces the need for building full commercialization capabilities, offers non-dilutive funding opportunities, and provides a repeatable pathway to monetize assets upon clinical progress.

Bears Say

No Current Product RevenueWith zero trailing-twelve-month revenue and ongoing net losses, the company lacks product-derived cash flow. This structural absence of revenue forces reliance on external financing or deals, elevating dilution and execution risk until a candidate achieves regulatory approval and commercial sales.

Negative Equity And Thin Asset BaseNegative shareholders' equity and a very small asset base constrain financial flexibility and increase solvency risk. Limited tangible assets and existing debt reduce borrowing options, weaken negotiating leverage with partners, and make the company more sensitive to adverse trial or funding outcomes.

Ongoing Cash Burn And Volatile Free Cash FlowPersistent negative operating and free cash flow with volatile FCF growth indicate structural cash burn. This durable funding gap necessitates repeated external financing or partner funding, constrains the ability to advance multiple programs, and increases the chance of dilution or financing on unfavorable terms.

Arch Biopartners News

Arch Biopartners publishes data linking cytokine IL-32 to inflammation, DKD

Arch Biopartners (ACHFF) announced that a scientific team led by Dr. Justin Chun at the University of Calgary...

4M ago

Arch Biopartners appoints Patrick Vink as chairman of the board

Arch Biopartners (ACHFF) announced the appointment of Dr. Patrick Vink as Chairman of the Company’s Board of Directors,...

5M ago

Arch granted ethics approval for St. Michaels participation in Phase II trial

Arch Biopartners (ACHFF) announced that the University Health Network Research Ethics Board has granted ethics approval for St....

6M ago

Arch Biopartners’ LSALT Peptide Study: A Promising Step in AKI Prevention

Arch Biopartners (($TSE:ARCH)) announced an update on their ongoing clinical study. Arch Biopartners is conducting a Phase 2...

8M ago

ARCH

ARCH FAQ

What was Arch Biopartners’s price range in the past 12 months?

Arch Biopartners lowest stock price was C$0.39 and its highest was C$1.93 in the past 12 months.

What is Arch Biopartners’s market cap?

Arch Biopartners’s market cap is C$32.27M.

When is Arch Biopartners’s upcoming earnings report date?

Arch Biopartners’s upcoming earnings report date is Aug 27, 2026 which is in 75 days.

How were Arch Biopartners’s earnings last quarter?

Arch Biopartners released its earnings results on Jun 02, 2026. The company reported -C$0.008 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.008.

Is Arch Biopartners overvalued?

According to Wall Street analysts Arch Biopartners’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Arch Biopartners pay dividends?

Arch Biopartners does not currently pay dividends.

What is Arch Biopartners’s EPS estimate?

Arch Biopartners’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Arch Biopartners have?

Arch Biopartners has 67,933,290 shares outstanding.

What happened to Arch Biopartners’s price movement after its last earnings report?

Arch Biopartners reported an EPS of -C$0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.769%.

Which hedge fund is a major shareholder of Arch Biopartners?

Currently, no hedge funds are holding shares in TSE:ARCH

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Arch Biopartners

Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address or avert dipeptidase-1 driven inflammation in critical organs such as the lungs, liver, and kidneys. This inflammatory response can lead to profound organ dysfunction or complete failure, particularly in conditions like sepsis and COVID-19. Moreover, Arch Biopartners is developing AB569, an experimental medication intended to combat antibiotic-resistant bacterial infections, primarily through topical application on wounds. Their innovative product pipeline also features Borg, a specialized peptide-solid surface interface developed to hinder biofilm formation and lessen material corrosion. Lastly, MetaMx involves synthetic compounds engineered to target the cells that initiate brain tumors and invasive glioma cells. The company's operations are based out of Toronto, Canada.